Of note, in the SURPASS-4 trial, adjudicated major adverse cardiovascular events (MACE) were not increased with tirzepatide compared with insulin glargine over an extended follow-up period of 52 additional weeks after the main trial period of 52 weeks [21]
But if you haven't had a period in 12 months and you're over 45, your menopause
DiNicolantonio JJ, Lavie CJ, Fares H, Menezes AR, OKeefe JH: L-carnitine in the secondary prevention of cardiovascular disease: systematic review and meta-analysis
Also, long-term safety data is still limited since it is only in Phase 3 especially around muscle loss vs fat loss, cardiovascular outcomes beyond surrogate markers, and durability after discontinuation
Will weight loss with GLP-1s make my skin sag